Stoke Therapeutics (NASDAQ:STOK) Trading 4.9% Higher

Stoke Therapeutics, Inc. (NASDAQ:STOK) traded up 4.9% during mid-day trading on Wednesday . The stock traded as high as $11.88 and last traded at $11.80. 74,849 shares traded hands during trading, a decline of 92% from the average session volume of 964,414 shares. The stock had previously closed at $11.25.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Thursday, April 4th. Canaccord Genuity Group upped their price target on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, March 26th. Wedbush upped their price target on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a research report on Tuesday, March 26th. JPMorgan Chase & Co. upped their price target on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a research report on Tuesday, March 26th. Finally, TD Cowen upgraded shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 26th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.63.

Stoke Therapeutics Stock Performance

The stock’s fifty day moving average price is $9.29 and its two-hundred day moving average price is $6.21.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Monday, March 25th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.02. The firm had revenue of $2.80 million for the quarter, compared to analysts’ expectations of $3.70 million. As a group, research analysts predict that Stoke Therapeutics, Inc. will post -2.28 EPS for the current year.

Insider Transactions at Stoke Therapeutics

In related news, major shareholder Skorpios Trust sold 3,600,000 shares of the stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total value of $41,760,000.00. Following the completion of the transaction, the insider now directly owns 10,843,681 shares of the company’s stock, valued at $125,786,699.60. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, major shareholder Skorpios Trust sold 3,600,000 shares of the stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total value of $41,760,000.00. Following the completion of the transaction, the insider now directly owns 10,843,681 shares of the company’s stock, valued at $125,786,699.60. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Edward M. Md Kaye sold 11,150 shares of the stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $68,015.00. Following the completion of the transaction, the chief executive officer now directly owns 69,350 shares of the company’s stock, valued at $423,035. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,632,741 shares of company stock worth $41,983,115. Company insiders own 12.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in STOK. Lynx1 Capital Management LP bought a new stake in shares of Stoke Therapeutics during the third quarter valued at approximately $6,738,000. GSA Capital Partners LLP increased its position in shares of Stoke Therapeutics by 514.7% during the third quarter. GSA Capital Partners LLP now owns 348,069 shares of the company’s stock valued at $1,371,000 after acquiring an additional 291,443 shares in the last quarter. Birchview Capital LP increased its position in shares of Stoke Therapeutics by 147.1% during the fourth quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock valued at $1,105,000 after acquiring an additional 125,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Stoke Therapeutics by 9.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 146,076 shares of the company’s stock valued at $576,000 after acquiring an additional 12,478 shares in the last quarter. Finally, Trexquant Investment LP increased its position in shares of Stoke Therapeutics by 166.9% during the third quarter. Trexquant Investment LP now owns 127,581 shares of the company’s stock valued at $503,000 after acquiring an additional 79,785 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.